Brand Intelligence Graph
Company Overview
About Addition Therapeutics
Addition Therapeutics emerged from stealth in December 2025 with $100 million in financing backed by the Gates Foundation, SR One, and Abingworth, developing PRINT — a platform using lipid nanoparticles (LNPs) to deliver RNA and enzyme payloads that integrate therapeutic sequences at specific genomic loci. Unlike traditional AAV gene therapy (which requires viral vectors and can only be dosed once due to immune response), PRINT's non-viral approach is potentially re-dosable, opening gene therapy to chronic diseases beyond rare genetic disorders.
Business Model & Competitive Advantage
The Gates Foundation's cornerstone role is the most significant signal: the foundation does not invest in biotechnology for financial returns — it invests in technologies with potential to address health challenges at global scale, particularly in low- and middle-income countries. A $100 million backing from Gates at stealth exit validates that PRINT's platform has credibility beyond rare Western diseases, likely targeting conditions like infectious disease, anemia, or metabolic disorders where gene therapy could have massive population-level impact.
Competitive Landscape 2025–2026
The re-dosable nature of PRINT is its core clinical advantage: all existing AAV gene therapies are one-time treatments because the immune system mounts an antibody response that prevents re-dosing. PRINT's LNP delivery avoids viral capsid immunogenicity, theoretically enabling booster dosing as needed — a critical advantage for diseases where a single gene therapy dose may not provide lifetime correction.
Key Differentiators
Emerging Innovator
Addition Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Vivtex
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historicall
Prime Medicine
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable
Compare Addition Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Addition Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Addition Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Addition Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →